INDUCTION OF PROTECTIVE IMMUNITY AGAINST CHLAMYDIA
诱导针对衣原体的保护性免疫力
基本信息
- 批准号:6331908
- 负责人:
- 金额:$ 32.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-09-01 至 2006-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by the applicant): Genital infection by the obligate
intracellular pathogen, Chlamydia trachomatis, is the most common bacterial
sexually transmitted disease (STD) in the United States, with four million
reported annual cases that cost over $2 billion. Of major pathophysiological
significance is the propensity for cervical infection in women to spread into
the upper genital tract, provoking serious complications such as pelvic
inflammatory disease, fallopian tube scarring, ectopic pregnancy and
infertility. Also, the frequently asymptomatic infections do cause severe
irreversible complications to be the first evidence of an infection. There are
concerns that genital chlamydial disease, like certain other STDs, such as AIDS
and gonococcal disease, may pose a serious threat to human reproduction,
well-being and healthcare costs. Current control and prevention strategies
target frequent screening for early detection and treatment, and development of
vaccines as the priority. The search for a chlamydial vaccine has led to
extensive research to define the crucial immune effectors in anti-chlamydial
immunity, identify antigens that elicit protective immunity, and design
effective methods of vaccine delivery. Our research has been focused on
identifying the relevant immune parameters in chlamydial immunity and
elucidating the mechanism(s) of intraepithelial inhibition of chlamydiae. Our
findings and reports by others have culminated in a new paradigm for designing
vaccines against Chlamydia based on the induction of local mucosal TH1
response. The major challenge at this stage is to select an appropriate
immunogen(s) and design an effective delivery system, to induce high levels of
local genital mucosal Th1 response to maintain long-term immunity. Accordingly,
this proposal uses immunological, genetic engineering, molecular, cellular and
biochemical techniques to investigate the central hypothesis that protective
anti-chlamydial immunity will be established if immunogenic chlamydial
antigen(s) are effectively delivered to induce high frequency of specific Th1
cells in the genital mucosa. Specific studies planned will use genetically
engineered and wild type mice to: (a) investigate the efficacy of genetically
designed recombinant multi-subunit vaccines composed of mucosal bacterial
ghosts co-expressing multiple membrane proteins of C. trachomatis; (b) assess
the therapeutic benefits of an immunotherapeutic cellular vaccine based on
IL-lO gene-suppressed dendritic cells presenting antigens for inducing high
frequency of specific Th1 response, as an alternative therapeutic vaccine for
C. trachomatis; (c) identify the major mucosal inductive sites,
antigen-presenting cells and other accessory cells crucial for Th1 activation;
and (d) define the molecular and cellular elements regulating Th1 activation,
trafficking and recruitment into the genital mucosa following effective
cellular and subunit vaccination against C. trachomatis. Results from these
studies will likely lead to the development of a reliable vaccine regimen
against Chlamydia, which should have major implications for the genital,
ocular, and lung infections and their complications.
描述(由申请人提供):义务人的生殖器感染
细胞内病原体沙眼衣原体是最常见的细菌
在美国,有 400 万人患有性传播疾病 (STD)
每年报告的案件花费超过 20 亿美元。主要病理生理学
重要的是女性宫颈感染传播到其他地方的倾向
上生殖道,引发严重的并发症,例如盆腔
炎症性疾病、输卵管疤痕、宫外孕和
不孕症。此外,频繁的无症状感染确实会导致严重的
不可逆的并发症是感染的第一个证据。有
担心生殖器衣原体疾病,就像某些其他性传播疾病,例如艾滋病
和淋菌病,可能对人类生殖构成严重威胁,
福祉和医疗保健费用。当前的控制和预防策略
以频繁筛查为目标,以实现早期发现和治疗,并开发
疫苗为优先。对衣原体疫苗的研究导致
广泛的研究来确定抗衣原体中关键的免疫效应子
免疫,识别引发保护性免疫的抗原,并设计
有效的疫苗接种方法。我们的研究一直集中在
识别衣原体免疫中的相关免疫参数和
阐明衣原体上皮内抑制的机制。我们的
其他人的发现和报告最终形成了一种新的设计范式
基于局部粘膜 TH1 诱导的衣原体疫苗
回复。这个阶段的主要挑战是选择合适的
免疫原并设计有效的递送系统,以诱导高水平的免疫原
生殖器局部粘膜的Th1反应可维持长期免疫力。因此,
该提案使用了免疫学、基因工程、分子、细胞和
生化技术来研究保护性的中心假设
如果衣原体具有免疫原性,则将建立抗衣原体免疫力
有效递送抗原以诱导高频率的特定 Th1
生殖器粘膜中的细胞。计划的具体研究将使用基因
工程小鼠和野生型小鼠:(a) 研究基因的功效
设计了由粘膜细菌组成的重组多亚单位疫苗
共表达沙眼衣原体多种膜蛋白的鬼影; (b) 评估
基于免疫治疗细胞疫苗的治疗益处
IL-10基因抑制的树突状细胞呈递抗原以诱导高
特定 Th1 反应的频率,作为替代治疗疫苗
沙眼衣原体; (c) 确定主要的粘膜感应位点,
抗原呈递细胞和其他对 Th1 激活至关重要的辅助细胞;
(d) 定义调节 Th1 激活的分子和细胞元件,
有效后贩运和募集到生殖器粘膜
针对沙眼衣原体的细胞和亚单位疫苗接种。这些结果
研究可能会导致开发出可靠的疫苗方案
对抗衣原体,这应该对生殖器产生重大影响,
眼部和肺部感染及其并发症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Francis O. Eko其他文献
Genital tract microbiome dynamics are associated with time of Chlamydia infection in mice
小鼠生殖道微生物群动态与衣原体感染时间相关
- DOI:
10.1101/2022.07.18.500533 - 发表时间:
2022 - 期刊:
- 影响因子:4.6
- 作者:
Lihong Zhao;Stephanie R. Lundy;Francis O. Eko;Joeseph U. Igietseme;Y. Omosun - 通讯作者:
Y. Omosun
Francis O. Eko的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Francis O. Eko', 18)}}的其他基金
INDUCTION OF PROTECTIVE IMMUNITY AGAINST CHLAMYDIA
诱导针对衣原体的保护性免疫力
- 批准号:
6891300 - 财政年份:1996
- 资助金额:
$ 32.83万 - 项目类别:
INDUCTION OF PROTECTIVE IMMUNITY AGAINST CHLAMYDIA
诱导针对衣原体的保护性免疫力
- 批准号:
7889191 - 财政年份:1996
- 资助金额:
$ 32.83万 - 项目类别:
INDUCTION OF PROTECTIVE IMMUNITY AGAINST CHLAMYDIA
诱导针对衣原体的保护性免疫力
- 批准号:
6604977 - 财政年份:1996
- 资助金额:
$ 32.83万 - 项目类别:
INDUCTION OF PROTECTIVE IMMUNITY AGAINST CHLAMYDIA
诱导针对衣原体的保护性免疫力
- 批准号:
8639439 - 财政年份:1996
- 资助金额:
$ 32.83万 - 项目类别:
INDUCTION OF PROTECTIVE IMMUNITY AGAINST CHLAMYDIA
诱导针对衣原体的保护性免疫力
- 批准号:
8238357 - 财政年份:1996
- 资助金额:
$ 32.83万 - 项目类别:
INDUCTION OF PROTECTIVE IMMUNITY AGAINST CHLAMYDIA
诱导针对衣原体的保护性免疫力
- 批准号:
8446379 - 财政年份:1996
- 资助金额:
$ 32.83万 - 项目类别:
INDUCTION OF PROTECTIVE IMMUNITY AGAINST CHLAMYDIA
诱导针对衣原体的保护性免疫力
- 批准号:
8051700 - 财政年份:1996
- 资助金额:
$ 32.83万 - 项目类别:
相似海外基金
Development of highly-efficient and safe live bacterial vaccines using viability-controlable pathogens
利用活性可控的病原体开发高效、安全的活细菌疫苗
- 批准号:
20H03158 - 财政年份:2020
- 资助金额:
$ 32.83万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Bacterial Vaccines and Therapies - Building a Product Pipeline
细菌疫苗和疗法 - 建立产品线
- 批准号:
700096 - 财政年份:2012
- 资助金额:
$ 32.83万 - 项目类别:
GRD Proof of Market
Recombinant Attenuated Bacterial Vaccines Against Biodefense Agents
针对生物防御剂的重组减毒细菌疫苗
- 批准号:
8259119 - 财政年份:2011
- 资助金额:
$ 32.83万 - 项目类别:
Recombinant Attenuated Bacterial Vaccines Against Biodefense Agents
针对生物防御剂的重组减毒细菌疫苗
- 批准号:
8653527 - 财政年份:2011
- 资助金额:
$ 32.83万 - 项目类别:
Designing effective Gram negative bacterial vaccines
设计有效的革兰氏阴性细菌疫苗
- 批准号:
DP110104165 - 财政年份:2011
- 资助金额:
$ 32.83万 - 项目类别:
Discovery Projects
Recombinant Attenuated Bacterial Vaccines Against Biodefense Agents
针对生物防御剂的重组减毒细菌疫苗
- 批准号:
8075999 - 财政年份:2011
- 资助金额:
$ 32.83万 - 项目类别:
Recombinant Attenuated Bacterial Vaccines Against Biodefense Agents
针对生物防御剂的重组减毒细菌疫苗
- 批准号:
8463108 - 财政年份:2011
- 资助金额:
$ 32.83万 - 项目类别:














{{item.name}}会员




